Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment

Random-pattern skin flaps are widely applied to rebuild and restore soft-tissue damage in reconstructive surgery; however, ischemia and subsequent ischemia-reperfusion injury lead to FLAP necrosis and are major complications. Exenatide, a glucagon-like peptide-1 analog, exerts therapeutic benefits for diabetic wounds, cardiac injury, and nonalcoholic fatty liver disease. Furthermore, Exenatide is a known activator of Autophagy, which is a complex process of subcellular degradation that may enhance the viability of random skin flaps. In this study, we explored whether exenatide can improve skin FLAP survival. Our results showed that exenatide augments Autophagy, increases FLAP viability, enhances angiogenesis, reduces oxidative stress, and alleviates Pyroptosis. Coadministration of exenatide with 3-methyladenine and chloroquine, potent inhibitors of Autophagy, reversed the beneficial effects, suggesting that the therapeutic benefits of exenatide for skin flaps are due largely to Autophagy activation. Mechanistically, we identified that exenatide enhanced activation and nuclear translocation of TFE3, which leads to Autophagy activation. Furthermore, we found that exenatide activates the AMPK-SKP2-CARM1 and AMPK-mTOR signaling pathways, which likely lead to exenatide's effects on activating TFE3. Overall, our findings suggest that exenatide may be a potent therapy to prevent FLAP necrosis, and we also reveal novel mechanistic insight into exenatide's effect on FLAP survival.